Nicole Germino
Stock Analyst at Truist Securities
(3.22)
# 1,005
Out of 4,784 analysts
21
Total ratings
50%
Success rate
3.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $21 → $18 | $4.81 | +274.22% | 2 | Mar 5, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $77.99 | +38.48% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.82 | +509.76% | 5 | Jan 23, 2025 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $2.20 | +854.55% | 1 | Sep 25, 2024 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $10.62 | +125.99% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $8.20 | - | 2 | Sep 3, 2021 |
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Buy
Price Target: $21 → $18
Current: $4.81
Upside: +274.22%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $77.99
Upside: +38.48%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.82
Upside: +509.76%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $2.20
Upside: +854.55%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $10.62
Upside: +125.99%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $8.20
Upside: -